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Abstract The aim of the study was to determine the serum
levels of adiponectin, leptin and IL-1 β in elderly diabetic
patients with and without mild cognitive impairment (MCI)
and to examine the associations of these markers with clinical
and cognitive parameters. A biochemical evaluation was per-
formed of 62 seniors with type 2 diabetes (T2DM) and MCI,
and 132 seniors with T2DM but without MCI (controls).
Serum leptin and IL-1 β levels were higher and adiponectin
concentration was lower in MCI patients than controls. In
MCI subjects, adiponectin level was negatively correlated
with leptin, IL-1 β levels and BMI. Leptin concentration
was correlated with IL-1 β level. Univariate logistic regres-
sion models revealed that the factors which increased the like-
lihood of diagnosis of MCI in elderly patients with T2DM
were higher levels of HbA1c, leptin, IL-1 β and triglycerides,
as well as lower levels of adiponectin and HDL cholesterol.
Similarly, previous CVD, hypertension, hyperlipidemia, reti-
nopathy, nephropathy, hypoglycemia, longer duration of dia-
betes, increased number of co-morbidities, older age, fewer
years of formal education were found to be associated with
MCI. Themultivariable model indicated fewer years of formal
education, previous CVD, hypertension, increased number of
co-morbidities, higher HbA1c and IL-1 β levels and lower
adiponectin level. Elderly diabetic patients with MCI have
higher levels of leptin and IL-1 β and lower levels of
adiponectin. Further prospective studies are needed to deter-
mine the role of these markers in the progression to dementia.
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Introduction
Type 2 diabetes (T2DM) is a chronic disease with well-
established cross-sectional and longitudinal associations with
cognitive impairment (Cukierman et al. 2005; Munshi et al.
2006; Ott et al. 1996). Mild cognitive impairment (MCI) is
defined as a transition stage between normal aging and de-
mentia. Many studies indicate that T2DM is a risk factor for
MCI (Gorska-Ciebiada et al. 2014; Cheng et al. 2012; Kodl
and Seaquist 2008). On the other hand aging itself is also
related to cognitive dysfunction: the prevalence of MCI in
subjects aged 70 years and older is 14–18 % (Petersen et al.
2009; Sinclair et al. 2000).
Recent studies have suggested that inflammation may play
an important role in the presence and development of MCI
(Hermida et al. 2012; Gorska-Ciebiada et al. 2015; Umegaki
et al. 2011; Barnes et al. 2006).
IL-1 β is one of the proinflammatory cytokines involved in
damage of islet beta cells (Palmer et al. 1989). One study per-
formed in rats found that pancreatic tissues expressed elevated
levels of IL-1β, and IL-1β-driven inflammatory cascade in di-
abetes (Ehses et al. 2009). This imbalance between IL-1β and
IL-1 receptor antagonist leads to pancreatic islet inflammation
and release of insulin. Using a recombinant human IL-1 receptor
antagonist is one of the novel anti-inflammatory treatments
which lead to the correction of beta cells dysfunction and de-
creased systemic inflammation in T2DM (Akash et al. 2012).
There is also strong evidence that inflammation can pay a
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crucial role in the brain during Alzheimer’s disease. Lue et al.
(2012) propose that diabetes causes macro and microvascular
complications which impair blood–brain barrier function and
endothelial cell activation. Microglia in the brain became acti-
vated by vascular injury and start a process of functional and
morphological transformation and degeneration (Lue et al.
2012). Although many studies show increased expression of
inflammatory mediators and microglial activation in MCI and
dementia it has been hypothesized that pro-inflammatory cyto-
kines are derived from peripheral sources like adipose tissue. It
is possible that central and peripheral inflammation pathways
are responsible both for the neurodegeneration process. The
adipose tissue produces many pro-inflammatory cytokines in-
cluding IL-1β, IL 6, IL 18 and TNF-α (Monteiro and Azevedo
2010). The levels of these mediators were elevated in peripheral
blood of patients with Alzheimer Disease (Swardfager et al.
2010). Adipose tissue also produces also an pro-inflammatory
hormone: leptin. T2DM and obesity is associated with
hyperleptinemia and subsequent leptin resistance. Studies sug-
gest that leptin can act as a neuro-inflammatory signal, one
which may attract different immune cells and stimulate the pro-
duction of such cytokines as IL-1β (Lam and Lu 2007). The
leptin receptors are present in microglia and regulate the synthe-
sis of IL-1β. High levels of plasma leptin are associated with the
production of IL-1β (Lafrance et al. 2010). Thus, it has been
proposed that hyperleptinemia and leptin resistance may lead to
a higher inflammatory response in the brain (Misiak et al. 2012).
Another protein secreted by adipose tissue is adiponectin,
which is highly involved in modulation of insulin sensitivity,
homeostasis of glucose and fatty acids and anti-inflammatory
action (Ouchi et al. 2003). Adiponectin has also been de-
scribed to have neuroprotective activities with its receptors
located in the brain (Letra et al. 2014). A little literature data
is available concerning the protective role of adiponectin in
mild cognitive impairment. In one study reduced amounts of
subcutaneous fat and low levels of plasma adiponectin were
found to be associated with MCI in men (Kamogawa et al.
2010). Although the findings so far suggest that some inflam-
matory mediators and adipocytokines can be involved in cog-
nitive function in elderly subjects with T2DM are limited.
Therefore, the aim of the current study was firstly, to deter-
mine the serum levels of adiponectin, leptin and IL-1 β in
elderly diabetic patients with and without MCI, and secondly,
to examine the relationships between these three markers and
clinical and cognitive parameters.
Materials and methods
Study population
A survey was conducted among 194 unselected elders attend-
ing an outpatient clinic belonging to the Department of
Internal Medicine and Diabetology, University Hospital no
1, Lodz, Poland. A brief recruitment screening was conducted
by the investigators to identify potential participants based on
the following inclusion criteria: age 65 and over, diabetes type
2 diagnosed minimum 1 year earlier, ability to understand and
cooperate with study procedures. The exclusion criteria were
diagnosed depression or dementia, use of possible or known
cognition-impairing drugs in the previous 3 month, presence
of neoplasm, constant alcohol or substance abuse, severe vi-
sual, mobility, or motor coordination impairment, history of
head trauma, inflammatory or infectious brain disease, severe
neurological or psychiatric illness.
The first part of visit included a morning blood draw after a
10–12 h overnight fast, blood pressure measurements, height
and weight assessment and complete physical examination.
Capillary glucose level measurement was performed after
breakfast to ensure that participants were not hypoglycemic
at the time of cognitive testing. The second part of the visit
took place in a private area in the clinic. The subjects com-
pleted a questionnaire describing baseline demographics and
underwent cognitive testing.
Participant characteristics, clinical evaluation and risk
factor assessment
Demographic variables and possible risk factors were re-
corded in a standardized interview. Weight and height were
measured to calculate body mass index (BMI=weight/
height2 [Kg/ m2]). A detailed medical history of diabetes
type 2 was taken: diabetes duration, current treatment for
diabetes and complications if present, co-morbid diseases
of the patient (hyperlipidemia, hypertension, cardiovascu-
lar disease, lung disease, cancer, gastrointestinal tract dis-
eases and other) and their treatment. Educational level was
recorded in years of education. Diabetic vascular compli-
cations were assessed based on the existence of nephropa-
thy, retinopathy, neuropathy, cardiovascular disease (CVD)
and stroke. Hypertension was defined as either a history of
hypertension or use of any antihypertensive agents,
Hyperlipidemia defined as use of any lipid lowering agent
or an untreated serum LDL cholesterol level 2.6 mmol/l or/
and triglycerides 1.7 mmol/l.
Blood biochemistry
After overnight fasting, blood samples were taken by veni-
puncture to assess serum levels of glycosylated hemoglobin
(HbA1c), total cholesterol, triglycerides, low-density lipopro-
tein cholesterol (LDL-C) and high-density lipoprotein choles-
terol (HDL-C). All the parameters were measured in a central-
ized laboratory.
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Determination of serum adiponectin, leptin and IL-1 β
The serum levels of adiponectin, leptin and IL-1 β were de-
termined by Quantikine Human Immunoassay ELISA kit (R
& D System, Minneapolis, USA) according to the manufac-
turer’s instructions. Minimum detectable concentrations were:
0.246 ng/ml for adiponectin, 7.8 pg/ml for leptin, and 1 pg/ml
for IL-1 β.
Neuropsychological evaluations
All participants underwent the following tests: the Montreal
Cognitive Assessment (MoCA) (Nasreddine et al. 2005) to
evaluate the cognitive impairment, Katz Basic Activities of
Daily living (BADL) and Lawton Instrumental Activities of
Daily Living (IADL) questionnaires to collect information on
daily activities (Katz et al. 1970; Lawton and Brody 1969).
The MoCA tests 8 cognitive domains, visual-spatial ability,
attention, executive function, immediate memory, delayed
memory, language, abstraction, calculation, and orientation,
for a maximum total score of 30. The normal MoCA score
is ≥26, with one point added if the subject has fewer than
12 years of formal education. The MoCA is better than other
tools to detect MCI in the elderly patients with type 2 diabetes
(Alagiakrishnan et al. 2013). MCI was diagnosed based on
criteria established by the 2006 European Alzheimer’s
Disease Consortium which is the currently available standard
test (Petersen 2004; Portet et al. 2006). The criteria include:
cognitive complaints coming from the patients or their fami-
lies, the reporting of a decline in cognitive functioning relative
to previous abilities during the past year by the patient or
informant, cognitive disorders as evidenced by clinical evalu-
ation (impairment in memory or in another cognitive domain,
which in this study was assessed byMoCA), absence of major
repercussions on daily life (measured in our study by the Katz
BADL and Lawton IADL), and absence of dementia. The cut-
off points for MoCA scores (19/30) are recommended for the
diagnosis of ‘Dementia’- in epidemiological studies. Patients
with a score of 19 or below were excluded from the study as
suffering from dementia and referred to a psychiatrist for fur-
ther care.
Two groups of subjects were evaluated: group 1 - patients
with MCI and group 2 - patients without MCI (controls).
Ethics
The study was operated in accordance with theWorldMedical
Association’s Declaration of Helsinki. Each participant was
identified by a number to maintain privacy. The approval
was obtained from the independent local ethics committee of
the Medical University of Lodz (No RNN/420/13/KB). The
purpose, nature, and potential risks of the experiments were
fully explained to the subjects, and all subjects gave their
written, informed consent at the beginning of the study. The
study included only patients who were fully able to under-
stand and cooperate with the study procedures.
Statistical analysis
All continues results are presented as means±SD. Frequencies
and percentages were calculated to enable comparison of char-
acteristics between patients withMCI and controls. Normality
of distributions was assessed using the Shapiro-Wilk test.
The descriptive statistics for the categorical variables were
tested using the χ2, and the continuous variables using the
Student’s T-test or the Mann Whitney-U test where appli-
cable. Relationships were assessed using the Pearson’s
correlation analysis for normally distributed variables
and Spearman rank correlation for non-normally distribut-
ed variables. As many factors can influence the results,
the simple logistic regression was performed to select so-
called independent factors which increase the selection
risk of MCI in elderly patients with type 2 diabetes. The
independent variables entered in the model at step one
were: demographic variables (age, gender, education), du-
ration of diabetes, glycaemic control (HbA1c level), car-
diovascular diseases (MI, angina, stroke), cardiovascular
risk factors (BMI, smoking status, hyperlipidaemia, previ-
ous HA or use of HA drugs), microvascular complica-
tions, presence of hypoglycemia, number of co-morbid
conditions, and the levels of lipids, adiponectin, leptin
and IL-1 β. We choose variables based on current litera-
ture which can potentially can influence the results
(Cukierman-Yaffe et al. 2009; Umegaki et al. 2011;
Misiak et al. 2012) . Multivariable regression was then
used to select the Bstrongest^ factor from the independent
risk factors. All the significant variables with p<0.05 in-
cluded in simple logistic regression model were intro-
duced to this analysis. The multivariable model was opti-
mized, using a stepwise approach (backward elimination
with Wald criteria). Odds ratios (OR) were computed and
presented with the 95 % interval of confidence (CI). A p-
value of less than 0.05 was considered statistically signif-
icant. Statistica 10.0 (StatSoft, Poland, Krakow) was used
for analysis.
Results
The baseline characteristics of the study group
Tables 1 and 2 present the characteristics of type 2 dia-
betic elderly patients with and without MCI. The χ2 test
showed that patients with MCI were more often diagnosed
with CVD, hypertension, hyperlipidemia, retinopathy, ne-
phropathy and hypoglycemia compared to controls. No
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significant differences were found between the groups
with regard to sex, smoking habit, stroke, neuropathy,
type of concomitant disease or treatment. Furthermore,
the Mann–Whitney U-test and Student’s T-test showed
that patients with MCI tended to be older, less educated,
with a longer duration of diabetes, higher number of co-
morbidities, higher BMI , higher levels of HbA1c and
triglicerydes, and lower concentrations of HDL cholester-
ol (Table 3). MoCA score was significantly lower in sub-
jects with MCI compared with controls. Lastly, there were
no significant differences between the groups with regard
to total cholesterol and LDL cholesterol levels (p>0.05).
Table 1 Characteristics of type 2
diabetic elderly patients with and
without MCI





Gender, Female 32 (51.6 %) 50 (37.8 %) 3.26 0.07
Smoked tobacco regularly 12 (19.4 %) 34 (25.7 %) 0.96 0.32
Macrovascular complications
Previous CVD 48 (77.4 %) 28 (21.2 %) 55.93 P<0.001
Stroke 2 (3.2 %) 5 (3.78 %) 0.04 0.84
Previous HA/ use of HA drugs 60 (96.7 %) 93 (70.4 %) 17.53 P<0.001
Hyperlipidemia 56 (90.3 %) 86 (65.15 %) 13.62 P<0.001
Microvascular complications
Retinopathy 43 (69.4 %) 43 (32.6 %) 23.12 P<0.001
Nephropathy 32 (51.6 %) 38 (28.8 %) 9.53 0.002
Neuropathy 10 (16.1 %) 13 (9.8 %) 1.59 0.21
Treatment
OAD 61 (98.4 %) 126 (95.4 %) 1.04 0.31
Insulin 23 (37.1 %) 47 (35.6 %) 0.04 0.84
Hypoglycemia 38 (61.29 %) 48 (36.36 %) 3.88 0.048
MCI mild cognitive impairment, CVD cardiovascular disease, HA hypertension, OAD oral anti-diabetic drug.
Data are mean – SD values. χ2 test was used to test for significant differences
Table 2 Comparison of
concomitant disease and drug use
by type 2 diabetic elderly patients
with and without MCI






Lung disease (%) 11 (17.7 %) 14 (10.6 %) 1.91 0.16
Atrial fibrillation (%) 14 (22.6 %) 22 (16.6 %) 0.98 0.32
Heart failure (%) 16 (25.8 %) 22 (16.6 %) 2.24 0.13
Gastrointerstinal tract disease (%) 29 (46.7 %) 41 (31.1 %) 4.52 0.03
Kidney disease (%) 15 (24.2 %) 24 (18.2 %) 0.95 0.33




35 (56.5 %) 56 (42.4 %) 3.33 0.06
Angiotensin II receptor blockers % 25 (40.3 %) 49 (37.1 %) 0.18 0.67
Diuretics (%) 23 (37.1 %) 32 (24.2 %) 15.36 P<0.001
Calcium channel blockers (%) 20 (32.3 %) 39 (29.5 %) 0.15 0.7
a1-Blockers (%) 7 (11.3 %) 11 (8.3 %) 0.44 0.51
B-blockers (%) 43 (69.3 %) 48 (36.3 %) 18.44 P<0.001
Antiplatelet medications (%) 48 (77.4 %) 69 (52.6 %) 10.8 0.001
Lipid-lowering medications (%) 42 (67.7 %) 89 (67.4 %) 0.01 0.96
MCI - mild cognitive impairment, Data are mean – SD values. χ2 test was used to test for significant differences
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Serum levels of adiponectin, leptin and IL-1 β in MCI
subjects and controls
Serum levels of leptin and IL-1 βwere significantly increased
in patients with MCI compared to controls (p<0.001). Serum
concentrations of adiponectin were lower in subjects with
cognitive impairment (Table 3). In the group of diabetic elder-
ly patients with MCI adiponectin level was negatively corre-
lated with leptin level (r=−0.64, p<0.001), with IL-1 β level
(r=−0.7, p<0.001) and with BMI (r=−0.78, p<0.001). Leptin
concentration was positively correlated with IL-1 β level (r=
0.54, p<0.001). Furthermore, both leptin and IL-1 β levels
were highly correlated with BMI. A positive but weak corre-
lation was found between IL-1β level andMoCA score, and a
negative correlation between adiponectin level and MoCA
score. Leptin level was inversely correlated with HDL choles-
terol level. The results are presented in Table 4. Since the
levels of adipokines, as leptin and adiponectin, are dependent
of body fat mass content and the group with T2DM and MCI
had significantly higher BMI values than the other group, we
divided all subjects into groups adjusted for BMI (Table 5).
We observed that the adipokines results observed between the
2 groups persist significant after statistical adjustment for
BMI. The only doubt occurs in group of patients with BMI
below 25.9, however among subjects with MCI only 5 per-
sons had such low BMI values therefore these data should be
interpreted with caution. The majority of patients had BMI
higher than 26 and in those we observed that elderly diabetic
patients with MCI have higher levels of leptin and IL-1 β and
lower levels of adiponectin.
Logistic regression models
The univariate logistic regression models revealed that the
variables which increased the likelihood of diagnosis of
MCI in elderly patients with type 2 diabetes were: higher
levels of HbA1c, leptin, IL-1 β and triglycerides, lower levels
of adiponectin and HDL cholesterol, presence of CVD, hy-
pertension, hyperlipidemia, retinopathy or nephropathy, hypo-
glycemia, longer duration of diabetes, increased number of co-
morbidities, older age and fewer years of formal education
(Table 6). Table 7 presents the risk factors for MCI according
to multivariable regression. It found that the factors increasing
the likelihood of having MCI in elderly patients with type 2
diabetes were fewer years of formal education, the presence of
previous CVD and hypertension, increased number of co-
morbidities, poorer glycaemic control (higher HbA1c level),
higher levels of IL-1 β and lower level of adiponectin.
Discussion
Serum levels of leptin and IL-1 β were found to be signifi-
cantly increased in patients with MCI compared to controls.
Furthermore leptin concentration was positively correlated
with IL-1 β level. These findings are consistent with the
Table 3 Clinical characteristics
and biochemical parameters of
type 2 diabetic elderly patients
with and without MCI





Age (years) 74.7±3.9 72.5±4.9 −3.39 P<0.001
Education-years 9.8±1.9 12.1±2.2 6.72 P<0.001
Duration of T2DM (years) 10.63±6.2 6.45±5.07 −5.59 P<0.001
BMI (kg/m2) 29.8±3.5 28.6±3.1 −2.48 0.01
Adiponectin (μg/ml) 6.06±4.26 10.02±4.4 5.53 P<0.001
Leptin (ng/ml) 25.19±12.09 18.11±8.26 −3.69 P<0.001
IL-1 β (ng/ml) 1.59±7.69 1.08±5.68 −4.44 P<0.001
HbA1c (%) 7.62±0.69 7±0.5 −5.83 P<0.001
CHOL-C (mmol/L) 10.13±2.2 9.58±1.76 −1.86 0.06
LDL-C (mmol/L) 5.79±1.49 5.64±1.5 −1.15 0.24
TG (mmol/L) 10.29±2.66 9.24±1.79 −5.04 P<0.001
HDL-C (mmol/L) 2.36±0.64 2.66±0.44 4.61 P<0.001
Co-morbidity (n) 6.3±3.06 2.8±1.8 −7.26 P<0.001
MoCA score 21.5±1.5 27.3±1.2 11.21 P<0.001
Katz BADL score 4.95±0.21 4.96±0.19 0.11 0.9
Lawton IADL score 7.98±0.12 8±0.01 0.17 0.85
T2DM diabetes type 2, BMI body mass index,CHOL total cholesterol;HbA1c glycosylated hemoglobin;HDL-C
high-density lipoprotein cholesterol; LDL-C low density lipoprotein cholesterol; TG triglycerides; MoCA -
Montreal Cognitive Assessment; BADL Basic Activities of Daily living, IADL Instrumental Activities of Daily
Living, Data are mean – SD values. Mann–Whitney U test (Z), or t test was used to test for significant differences
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hypothesis that low-grade systemic inflammation is associated
with dementia and MCI. Although the involvement of
hyperleptinemia has been suggested to play a role in the pro-
inflammatory state, and elevated IL-1 β levels may be asso-
ciated with the deterioration of cognition in diabetes, data
about these mediators in elderly MCI subjects with T2DM is
poor. Our present findings go some way to addressing this
paucity of evidence.
Although IL-1β is quite frequently described in
Alzheimer’s disease, whereas only few reports have investi-
gated its levels in MCI (Brosseron et al. 2014). The Sydney
Memory and Aging Study found higher levels of Interleukin-
1β (IL-1β), Tumor Necrosis Factor-α (TNF-α) and
Interleukin 12 in the members of the non-amnesticMCI group
compared to those with normal cognitive function (Trollor
et al. 2010). In other studies, increased levels of TNF-α and
IL-1β were found in the cerebrospinal fluid and plasma in
patients with Alzheimer’s disease (Holmes et al. 2009;
Forlenza et al. 2009). Inflammatory cytokines and other me-
diators are found in senile plaques from brains with dementia.
It has been hypothesized that in a state of peripheral insulin-
resistance, insulin may cross the blood brain barrier and stim-
ulate the overproduction of proinflammatory cytokines
(Misiak et al. 2012).
Another marker of low-grade inflammation is leptin.
Leptin is a hormone derived from adipose tissues.
Hyperleptinemia and subsequent leptin resistance are associ-
ated with T2DM and obesity (Letra et al. 2014). A body of
evidence suggests that leptin, and other adipocytokines might
be involved in pathogenesis of deterioration of cognition and
dementia (Misiak et al. 2012; Letra et al. 2014). One study
associates leptin levels with cognitive function in older adults
(Holden et al. 2009). Similarly, other studies of older adults
with T2DM diabetes indicate that higher leptin levels were
associated with worse cognitive function in men, but were
not associated with cognitive function in women (Labad
et al. 2012). However, a recently published study found no
association between plasma leptin level and cognitive func-
tion at baseline and over 3-year follow-up period inMCI older
adults (Oania and McEvoy 2015). One study performed in
middle-aged and elderly participants who were apparently
healthy found no difference in leptin plasma levels between
Table 4 Relationship of serum
levels of adiponectin, leptin and
IL-1 β with other clinical
indicators in group of diabetic







MoCA score −0.3* 0.016 0.02 0.85 0.38* 0.002
HbA1c (%) −0.18 0.14 0.12 0.33 0.07 0.56
CHOL mmol/l) −0.06 0.63 0.02 0.84 0.001 0.98
LDL (mmol/l) −0.11 0.09 0.09 0.44 0.12 0.34
TG (mmol/l) −0.23 0.06 0.2 0.11 0.01 0.92
HDL (mmol/l) 0.24 0.06 −0.3* 0.017 −0.1 0.42
BMI (kg/m2) −0.78* P<0.001 0.71* P<0.001 0.83* P<0.001
Adiponectin (μg/ml) 1
Leptin (ng/ml) −0.64* P<0.001 1
IL-1 β (ng/ml) −0.7* P<0.001 0.54* P<0.001 1
*significance, p<0.05; r-correlation coefficient
BMI body mass index; CHOL total cholesterol; HbA1c glycosylated hemoglobin; HDL-C high-density lipopro-
tein cholesterol; LDL-C low density lipoprotein cholesterol; TG triglycerides; MoCA Montreal Cognitive
Assessment
Table 5 Serum levels of adiponectin, leptin and IL-1 β in type 2
diabetic elderly patients with and without MCI according to BMI values






BMI≤25.9 13.04±3.98 13.5±3.83 0.27 0.78
BMI 26–27.9* 9.37±3.33 11.76±3.05 2.68 0.009
BMI 28–29.9* 6.14±2.85 10.38±2.77 4.34 <0.001
BMI≥30* 2.89±1.59 5.44±3.78 3.39 0.001
Leptin (ng/ml)
BMI≤25.9 7.6±2.94 8.4±5.28 0.32 0.74
BMI 26–27.9* 19.29±5.0 15.6±5.43 −2.43 0.017
BMI 28–29.9* 21.76±8.65 17.94±3.34 −2.11 0.04
BMI≥30* 32.98±11.5 27.03±7.31 −2.51 0.014
IL-1 β (ng/ml)
BMI≤25.9* 8.82±0.71 6.6±2.23 −2.16 0.04
BMI 26–27.9 9.4±0.75 9.27±1.47 −0.33 0.73
BMI 28–29.9* 13.56±3.44 9.96±1.18 −5.17 <0.001
BMI≥30* 21.97±1.51 16.09±8.6 −2.94 0.004
*significance, p<0.05
MCI mild cognitive impairment, BMI body mass index. Data are mean –
SD values. Mann–Whitney U test (Z), or t test was used to test for sig-
nificant differences
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subjects with and without MCI (Kamogawa et al. 2010).
Although these studies contradict our present findings, they
were performed in a general, non-diabetic, population. In di-
abetes, leptin function may be modulated by a number of
factors, including the ratio between free and bound leptin,
local leptin levels, the expression of different forms of the
receptors, and the presence of specific inhibitors and inflam-
mation (Fantuzzi and Faggioni 2000). One study showed that
elderly obese subjects with higher leptin levels showed con-
comitant greater global brain atrophy, suggesting that brain
Table 6 Assessment results of
the risk of havingMCI in a simple
logistic regression model in the
patients with type 2 diabetes
Variables analyzed ß SE of ß p value OR 95 % CI
Age (years)* 0.1 0.03 0.003 1.1 1.03–1.18
Gender: female 0.28 0.15 0.07 1.3 0.95–1.79
Education (years)* −0.62 0.11 P<0.001 0.54 0.44–0.66
Smoked tobacco regularly 0.18 0.08 0.33 1.2 0.83–1.74
Duration of DM2 (years)* 0.13 0.03 P<0.001 1.14 1.07–1.21
Previous stroke 0.4 0.08 0.84 1.08 0.47–2.5
Previous CVD* 1.27 0.18 P<0.001 3.57 2.48–5.13
Previous HA or use of HA drugs* 1.26 0.37 0.001 3.54 1.71–7.35
Hyperlipidemia* 0.8 0.23 0.001 2.23 1.41–3.53
Retinopathy* 0.77 0.16 P<0.001 2.16 1.56–2.99
Nephropathy* 0.48 0.15 0.002 1.62 1.18–2.22
Neuropathy 0.28 0.22 0.21 1.32 0.85–2.06
Co-morbidity (n)* 0.55 0.08 P<0.001 1.74 1.48–2.04
BMI (kg/m2) 0.11 0.04 0.15 1.12 1.02–1.23
HbA1c (%)* 1.64 0.28 P<0.001 5.2 2.95–9.14
CHOL mmol/l) 0.01 0.004 0.06 1.01 0.99–1.02
LDL (mmol/l) 0.01 0.006 0.51 1.004 0.99–1.02
TG (mmol/l)* 0.01 0.005 0.002 1.014 1.005–1.02
HDL (mmol/l)* −0.07 0.01 P<0.001 0.93 0.89–0.96
adiponectin (μg/ml)* −0.21 0.04 P<0.001 0.81 0.74–0.87
Leptin (ng/ml)* 0.07 0.01 P<0.001 1.07 1.03–1.11
IL-1 beta (ng/ml)* 0.11 0.02 P<0.001 1.12 1.06–1.17
Hypoglycemia* 1.02 0.31 0.0013 2.7 1.48–5.15
Abbreviations: ß: regression coefficient;CI: confidence interval for odds ratio;OR: odds ratio; SE: standard error;
*significance, p<0.05
DM diabetes mellitus,CVD cardiovascular disease,HA hypertension,MCImild cognitive impairment, BMI body
mass index,HbA1c glycosylated hemoglobin,CHOL total cholesterol;HDL high-density lipoprotein cholesterol;
LDL low density lipoprotein cholesterol; TG triglycerides
Table 7 Assessment results of
the risk of having MCI in a
multivariable logistic regression
model in the patients with type 2
diabetes
Variables analyzed ß SE of ß p value OR 95 % CI
Education (years)* −0.37 0.13 0.006 0.68 0.52–0.9
Previous CVD* 0.67 0.26 0.01 1.96 1.16–3.31
Previous HA or use of HA drugs* 1.12 0.46 0.017 3.06 1.22–7.68
Co-morbidity (n)* 0.26 0.1 0.012 1.3 1.06–1.59
HbA1c (%)* 0.93 0.39 0.019 2.54 1.16–5.58
adiponectin (μg/ml)* −0.21 0.08 0.011 0.81 0.68–0.95
IL-1 beta (ng/ml)* 0.12 0.05 0.025 1.13 1.01–1.25
Abbreviations: ß regression coefficient; CI confidence interval for odds ratio; OR odds ratio; SE standard error;
*significance, p<0.05
CVD cardiovascular disease, HA hypertension, MCI mild cognitive impairment, HbA1c glycosylated
hemoglobin
Metab Brain Dis (2016) 31:257–266 263
resistance to its action may develop in obese individuals de-
spite peripheral hyperproduction of leptin (Rajagopalan et al.
2013).
Another marker of adipose tissue dysfunction is
adiponectin. Adiponectin has well known protective role
against insulin resistance, atherosclerosis and anti-
inflammatory activity. Recent data indicates that adiponectin
levels in elderly patients with T2DM seem to be closely linked
to obesity and length of disease (Coimbra et al. 2014). In our
study serum concentrations of adiponectin were lower in sub-
jects with MCI. Similarly, Teixeira et al. (2013)) report lower
levels of adiponectin to be associated with cognitive dysfunc-
tion, although these do not predict additional cognitive decline
or conversion to dementia in this cohort of elderly subjects.
They propose that decreased adiponectin may be a surrogate
marker of the pathological process in Alzheimer’s Disease,
linking clinical comorbidities, inflammation and cognitive
dysfunction. Kamogawa et al. (2010) observed that reduced
amounts of subcutaneous fat and low levels of plasma
adiponectin were found to be associated with MCI in men.
Adiponectin may play a protective role in the progression of
early-stage cognitive impairment. It has been shown to have
neuroprotective effects on hippocampal cells (Jeon et al. 2009)
and a direct action on the neurons protecting human neuro-
blastoma cells from apoptosis (Jung et al. 2006). However,
one small study found adiponectin levels to be significantly
increased in individuals with MCI and AD compared to elder-
ly controls (Une et al. 2011) and another did not reveal any
significant difference in adiponectin level between AD sub-
jects and cognitively healthy older subjects (Bigalke et al.
2011). These contradictory results may be explained by dif-
ferences in sample size, characterization of the cognitive status
of included subjects, presence of clinical co-morbidities, pop-
ulation backgrounds and study settings. Therefore, additional
studies are necessary to evaluate the role of adiponectin and
other adipcytokines levels in the pathophysiology of MCI and
dementia.
Our present findings indicate that higher levels of IL-1 β
and lower levels of adiponectin are the factors increasing the
likelihood of MCI developing in elderly patients with type 2
diabetes, according to a multivariable model. Interestingly,
among many other factors adiponectin and IL-1 β levels are
associated with cognition independently. Increased
adiponectin levels are able to decrease the expression of such
inflammatory cytokines as NF-κB activation and TNF-α and
may induce the production of other anti-inflammatory mole-
cules including the IL-1 receptor antagonist and IL-10 (Misiak
et al. 2012; Ouchi et al. 2003; Fasshauer et al. 2003).
Therefore, lower adiponectin levels can stimulate pro-
inflammatory cascades leading to the low-grade inflammation
present inMCI and AD subjects. In addition, IL-1 β level was
found to be inversely correlated with adiponectin level and
positively associated with leptin concentration.
However, our study has some limitations that should be
kept in mind when interpreting our data.
Firstly, the study population was relatively small, which
may have limited our power to examine other associations.
Secondly, the study wasn’t designed as longitudinal inves-
tigation. There have been few studies in which the cognitive
declines in elderly diabetics were prospectively observed.
However, the precise mechanisms underlying T2DM-related
cognitive dysfunction or the development of dementia have
not yet been elucidated.
Thirdly, our participants were recruited from one
race/ethnicity, which may limit the generalizability of findings
to other populations.
Nevertheless, the results of this study suggest that further
inquiry into the direction andmagnitude of the pathways linking
cognitive impairment and type 2 diabetes, in elderly is warrant-
ed. Further studies are required in younger people and in those
without diabetes to determine the an association between low
grade inflammation, adipokines and cognitive dysfunction.
In conclusion, present study suggests that those elderly
diabetic patients with MCI, are more likely to have higher
levels of IL-1 β and leptin and lower levels of adiponectin.
Although our findings confirm the association between higher
levels of low-grade systemic inflammation, adipokines and
cognition, further prospective studies are needed to confirm
the role of these markers in the progression to dementia.
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